{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:45:39Z","timestamp":1759333539287},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T00:00:00Z","timestamp":1114732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To determine whether etanercept therapy enables long\u2010term psoriasis patients to discontinue systemic psoriatic therapy.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Charts from psoriatic patients on etanercept therapy seen at the Department of Dermatology and Dermatolgic Surgery, University of Miami, Miami, FL, USA, between June 2002 and October 2003, were evaluated retrospectively. The duration of disease, adverse events to \u201cstandard\u201d systemic psoriatic therapy, and current therapy were reviewed. IRB: 03\/582C.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A large proportion of patients (73.5%) were able to decrease or discontinue their traditional systemic agent while on etanercept.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Etanercept is a safe and effective therapy in chronic moderate to severe psoriasis. In patients who are receiving systemic therapy for their disease and alternative therapy is warranted, etanercept can be added with the aim to discontinue the other systemic agents.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2005.02626.x","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T16:10:53Z","timestamp":1123085453000},"page":"688-691","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Etanercept and psoriasis, from clinical studies to real life"],"prefix":"10.1111","volume":"44","author":[{"given":"Sharon E.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Sergay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco A.","family":"Kerdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Benchmark Survey on Psoriasis and Psoriatic Arthritis","author":"National Psoriasis Foundation","year":"2001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu354xx"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12040.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archderm.1996.03890300039008","article-title":"Long\u2010term safety of cyclosporine in the treatment of psoriasis","volume":"132","author":"Grossman RM","year":"1996","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361501"},{"key":"e_1_2_5_7_2","first-page":"1","article-title":"Etanercept, a TNF antagonist for treatment of psoriatic arthritis and psoriasis","volume":"8","author":"Mease PJ","year":"2003","journal-title":"Skin Ther Lett"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/mjd.2003.554"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"e_1_2_5_12_2","first-page":"S77","article-title":"Global safety and efficacy of up to 5 years of etanercept (Enbrel) therapy [abstract]","volume":"44","author":"Klareskog L","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_5_13_2","first-page":"33","article-title":"What are the risks of biologic therapy in rheumatoid arthritis? An update on safety","volume":"65","author":"Weisman MH","year":"2002","journal-title":"J Rheumatol (Suppl)"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg263"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00101-1"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(03)00047-4"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2005.02626.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2005.02626.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:37:31Z","timestamp":1696927051000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2005.02626.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1365-4632.2005.02626.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2005.02626.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,20]]},"assertion":[{"value":"2005-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}